{"analyses":[{"ciLowerLimit":"0.3730","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.6605","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Odds Ratio (OR)","paramValue":"0.4963","statisticalMethod":"Chi-squared","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2296"},{"groupId":"OG001","value":"886"}]}],"title":"30 MIU/day"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2313"},{"groupId":"OG001","value":"443"}]}],"title":"48 MIU/day"}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"1104"},{"groupId":"OG001","value":"328"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"4609"},{"groupId":"OG001","value":"1329"}],"units":"cycles"}],"description":"Objective 2: To describe EP2006 primary or secondary prophylaxis patterns for FN over up to 6 cycles of chemotherapy, with or without prior, concurrent, or later radiotherapy or surgery.","groups":[{"description":"Cancer patients with solid tumor treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006: Solid Tumor"},{"description":"Cancer patients with hematological tumor treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG001","title":"EP2006: Hematological Tumor"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"EP2006 Dose by Tumor Type: Cycle Level","type":"PRIMARY","typeUnitsAnalyzed":"cycles","unitOfMeasure":"cycles"}